The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neuromuscular Blocking Agent (NMBA) Market Research Report 2024
Synopsis
The global Neuromuscular Blocking Agent (NMBA) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neuromuscular Blocking Agent (NMBA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuromuscular Blocking Agent (NMBA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Neuromuscular Blocking Agent (NMBA) include AbbVie, GlaxoSmithKline, Pfizer, Hengrui Pharmaceutical, Abbott Laboratories, Fresenius Kabi, Sandoz, Somerset Therapeutics and Guike Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuromuscular Blocking Agent (NMBA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromuscular Blocking Agent (NMBA).
Report Scope
The Neuromuscular Blocking Agent (NMBA) market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromuscular Blocking Agent (NMBA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromuscular Blocking Agent (NMBA) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
GlaxoSmithKline
Pfizer
Hengrui Pharmaceutical
Abbott Laboratories
Fresenius Kabi
Sandoz
Somerset Therapeutics
Guike Pharmaceutical
Shanghai Pharmaceuticals
Themis Medicare
Nanjing King-Friend
Segment by Type
Depolarizing
Non-depolarizing
Segment by Application
Hospital
Clinic
Pharmacy
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neuromuscular Blocking Agent (NMBA) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neuromuscular Blocking Agent (NMBA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Neuromuscular Blocking Agent (NMBA) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neuromuscular Blocking Agent (NMBA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neuromuscular Blocking Agent (NMBA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Neuromuscular Blocking Agent (NMBA) include AbbVie, GlaxoSmithKline, Pfizer, Hengrui Pharmaceutical, Abbott Laboratories, Fresenius Kabi, Sandoz, Somerset Therapeutics and Guike Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuromuscular Blocking Agent (NMBA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromuscular Blocking Agent (NMBA).
Report Scope
The Neuromuscular Blocking Agent (NMBA) market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromuscular Blocking Agent (NMBA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromuscular Blocking Agent (NMBA) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
GlaxoSmithKline
Pfizer
Hengrui Pharmaceutical
Abbott Laboratories
Fresenius Kabi
Sandoz
Somerset Therapeutics
Guike Pharmaceutical
Shanghai Pharmaceuticals
Themis Medicare
Nanjing King-Friend
Segment by Type
Depolarizing
Non-depolarizing
Segment by Application
Hospital
Clinic
Pharmacy
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neuromuscular Blocking Agent (NMBA) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neuromuscular Blocking Agent (NMBA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Neuromuscular Blocking Agent (NMBA) Market Overview
1.1 Product Overview and Scope of Neuromuscular Blocking Agent (NMBA)
1.2 Neuromuscular Blocking Agent (NMBA) Segment by Type
1.2.1 Global Neuromuscular Blocking Agent (NMBA) Market Value Comparison by Type (2024-2030)
1.2.2 Depolarizing
1.2.3 Non-depolarizing
1.3 Neuromuscular Blocking Agent (NMBA) Segment by Application
1.3.1 Global Neuromuscular Blocking Agent (NMBA) Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Others
1.4 Global Neuromuscular Blocking Agent (NMBA) Market Size Estimates and Forecasts
1.4.1 Global Neuromuscular Blocking Agent (NMBA) Revenue 2019-2030
1.4.2 Global Neuromuscular Blocking Agent (NMBA) Sales 2019-2030
1.4.3 Global Neuromuscular Blocking Agent (NMBA) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Neuromuscular Blocking Agent (NMBA) Market Competition by Manufacturers
2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Neuromuscular Blocking Agent (NMBA) Average Price by Manufacturers (2019-2024)
2.4 Global Neuromuscular Blocking Agent (NMBA) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neuromuscular Blocking Agent (NMBA), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neuromuscular Blocking Agent (NMBA), Product Type & Application
2.7 Neuromuscular Blocking Agent (NMBA) Market Competitive Situation and Trends
2.7.1 Neuromuscular Blocking Agent (NMBA) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neuromuscular Blocking Agent (NMBA) Players Market Share by Revenue
2.7.3 Global Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario by Region
3.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Neuromuscular Blocking Agent (NMBA) Global Neuromuscular Blocking Agent (NMBA) Sales by Region: 2019-2030
3.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Region: 2019-2024
3.2.2 Global Neuromuscular Blocking Agent (NMBA) Sales by Region: 2025-2030
3.3 Global Neuromuscular Blocking Agent (NMBA) Global Neuromuscular Blocking Agent (NMBA) Revenue by Region: 2019-2030
3.3.1 Global Neuromuscular Blocking Agent (NMBA) Revenue by Region: 2019-2024
3.3.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Region: 2025-2030
3.4 North America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.4.1 North America Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2019-2030)
3.4.3 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.5.1 Europe Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2019-2030)
3.5.3 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.6.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Country (2019-2030)
3.6.3 Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.7.1 Latin America Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country (2019-2030)
3.7.3 Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.8.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2019-2030)
4.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2019-2024)
4.1.2 Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2025-2030)
4.1.3 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2019-2030)
4.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2019-2030)
4.2.1 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2019-2024)
4.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2025-2030)
4.2.3 Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2019-2030)
4.3 Global Neuromuscular Blocking Agent (NMBA) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2019-2030)
5.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2019-2024)
5.1.2 Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2025-2030)
5.1.3 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2019-2030)
5.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2019-2030)
5.2.1 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2019-2024)
5.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2025-2030)
5.2.3 Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2019-2030)
5.3 Global Neuromuscular Blocking Agent (NMBA) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Hengrui Pharmaceutical
6.4.1 Hengrui Pharmaceutical Corporation Information
6.4.2 Hengrui Pharmaceutical Description and Business Overview
6.4.3 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.4.5 Hengrui Pharmaceutical Recent Developments/Updates
6.5 Abbott Laboratories
6.5.1 Abbott Laboratories Corporation Information
6.5.2 Abbott Laboratories Description and Business Overview
6.5.3 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.5.5 Abbott Laboratories Recent Developments/Updates
6.6 Fresenius Kabi
6.6.1 Fresenius Kabi Corporation Information
6.6.2 Fresenius Kabi Description and Business Overview
6.6.3 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.6.5 Fresenius Kabi Recent Developments/Updates
6.7 Sandoz
6.6.1 Sandoz Corporation Information
6.6.2 Sandoz Description and Business Overview
6.6.3 Sandoz Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sandoz Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.7.5 Sandoz Recent Developments/Updates
6.8 Somerset Therapeutics
6.8.1 Somerset Therapeutics Corporation Information
6.8.2 Somerset Therapeutics Description and Business Overview
6.8.3 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.8.5 Somerset Therapeutics Recent Developments/Updates
6.9 Guike Pharmaceutical
6.9.1 Guike Pharmaceutical Corporation Information
6.9.2 Guike Pharmaceutical Description and Business Overview
6.9.3 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.9.5 Guike Pharmaceutical Recent Developments/Updates
6.10 Shanghai Pharmaceuticals
6.10.1 Shanghai Pharmaceuticals Corporation Information
6.10.2 Shanghai Pharmaceuticals Description and Business Overview
6.10.3 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.10.5 Shanghai Pharmaceuticals Recent Developments/Updates
6.11 Themis Medicare
6.11.1 Themis Medicare Corporation Information
6.11.2 Themis Medicare Neuromuscular Blocking Agent (NMBA) Description and Business Overview
6.11.3 Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Themis Medicare Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.11.5 Themis Medicare Recent Developments/Updates
6.12 Nanjing King-Friend
6.12.1 Nanjing King-Friend Corporation Information
6.12.2 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Description and Business Overview
6.12.3 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.12.5 Nanjing King-Friend Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neuromuscular Blocking Agent (NMBA) Industry Chain Analysis
7.2 Neuromuscular Blocking Agent (NMBA) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neuromuscular Blocking Agent (NMBA) Production Mode & Process
7.4 Neuromuscular Blocking Agent (NMBA) Sales and Marketing
7.4.1 Neuromuscular Blocking Agent (NMBA) Sales Channels
7.4.2 Neuromuscular Blocking Agent (NMBA) Distributors
7.5 Neuromuscular Blocking Agent (NMBA) Customers
8 Neuromuscular Blocking Agent (NMBA) Market Dynamics
8.1 Neuromuscular Blocking Agent (NMBA) Industry Trends
8.2 Neuromuscular Blocking Agent (NMBA) Market Drivers
8.3 Neuromuscular Blocking Agent (NMBA) Market Challenges
8.4 Neuromuscular Blocking Agent (NMBA) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
